Drug Trial Radar · NCT03605680
A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Last checked: Nov 20, 2026Latest source record: Mar 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
604
Actual
Start
Jan 16, 2019
Primary completion
Apr 11, 2020
Study completion Apr 11, 2020
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Jul 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder (ADHD). Participants will either receive a twice-daily dose of centanafadine sustained-release tablets, or twice-daily placebo.
Conditions
- Attention Deficit Disorder
- Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine SRDrug
100 mg, BID, oral tablets
PlaceboOther
BID, oral tablet.
Centanafadine SRDrug
200 mg, BID, oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS)Time frame: Baseline and Day 42
Locations
1 site in 1 country. Site status is shown where the registry gives one.
For additional information regarding sites, contact 844-687-8522
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.